AIMS: Breast adenomyoepitheliomas (AMEs) are uncommon tumours. Most oestrogen receptor (ER)-positive AMEs have mutations in phosphoinositide 3-kinase (PI3K) pathway genes, whereas ER-negative AMEs usually harbour concurrent mutations affecting the HRAS Q61 hotspot and PI3K pathway genes. Here, we sought to determine the sensitivity and specificity of RAS Q61R immunohistochemical (IHC) analysis for detection of HRAS Q61R mutations in AMEs. METHODS AND RESULTS: Twenty-six AMEs (14 ER-positive; 12 ER-negative) previously subjected to massively parallel sequencing (n = 21) or Sanger sequencing (n = 5) of the HRAS Q61 hotspot locus were included in this study. All AMEs were subjected to IHC analysis with a monoclonal (SP174) RAS Q61R-specific antibody, in addition to detailed histopathological analysis. Nine ER-negative AMEs harboured HRAS mutations, including Q61R (n = 7) and Q61K (n = 2) mutations. Five of seven (71%) AMEs with HRAS Q61R mutations were immunohistochemically positive, whereas none of the AMEs lacking HRAS Q61R mutations (n = 17) were immunoreactive. RAS Q61R immunoreactivity was restricted to the myoepithelium in 80% (4/5) of cases, whereas one case showed immunoreactivity in both the epithelial component and the myoepithelial component. RAS Q61R immunohistochemically positive AMEs were associated with infiltrative borders (P < 0.001), necrosis (P < 0.01) and mitotic index in the epithelial (P < 0.05) and myoepithelial (P < 0.01) components. RAS Q61R IHC assessment did not reveal Q61K mutations (0/2). CONCLUSIONS: IHC analysis of RAS Q61R shows high specificity (100%) and moderate sensitivity (71%) for detection of HRAS Q61R mutations in breast AMEs, and appears not to detect HRAS Q61K mutations. IHC analysis of RAS Q61R may constitute a useful technique in the diagnostic workup of ER-negative AMEs.
AIMS: Breast adenomyoepitheliomas (AMEs) are uncommon tumours. Most oestrogen receptor (ER)-positive AMEs have mutations in phosphoinositide 3-kinase (PI3K) pathway genes, whereas ER-negative AMEs usually harbour concurrent mutations affecting the HRAS Q61 hotspot and PI3K pathway genes. Here, we sought to determine the sensitivity and specificity of RAS Q61R immunohistochemical (IHC) analysis for detection of HRASQ61R mutations in AMEs. METHODS AND RESULTS: Twenty-six AMEs (14 ER-positive; 12 ER-negative) previously subjected to massively parallel sequencing (n = 21) or Sanger sequencing (n = 5) of the HRAS Q61 hotspot locus were included in this study. All AMEs were subjected to IHC analysis with a monoclonal (SP174) RAS Q61R-specific antibody, in addition to detailed histopathological analysis. Nine ER-negative AMEs harboured HRAS mutations, including Q61R (n = 7) and Q61K (n = 2) mutations. Five of seven (71%) AMEs with HRASQ61R mutations were immunohistochemically positive, whereas none of the AMEs lacking HRASQ61R mutations (n = 17) were immunoreactive. RAS Q61R immunoreactivity was restricted to the myoepithelium in 80% (4/5) of cases, whereas one case showed immunoreactivity in both the epithelial component and the myoepithelial component. RAS Q61R immunohistochemically positive AMEs were associated with infiltrative borders (P < 0.001), necrosis (P < 0.01) and mitotic index in the epithelial (P < 0.05) and myoepithelial (P < 0.01) components. RAS Q61R IHC assessment did not reveal Q61K mutations (0/2). CONCLUSIONS: IHC analysis of RAS Q61R shows high specificity (100%) and moderate sensitivity (71%) for detection of HRASQ61R mutations in breast AMEs, and appears not to detect HRASQ61K mutations. IHC analysis of RAS Q61R may constitute a useful technique in the diagnostic workup of ER-negative AMEs.
Authors: Anna Felisiak-Goląbek; Shingo Inaguma; Artur Kowalik; Bartosz Wasąg; Zeng-Feng Wang; Sebastian Zięba; Liliana Pięciak; Janusz Ryś; Janusz Kopczynski; Maarit Sarlomo-Rikala; Stanislaw Góźdź; Jerzy Lasota; Markku Miettinen Journal: Appl Immunohistochem Mol Morphol Date: 2018-01
Authors: Jong-Kyu Kim; Chan Yong Seong; In Eui Bae; Jin Wook Yi; Hyeong Won Yu; Su-Jin Kim; Jae-Kyung Won; Young Jun Chai; June Young Choi; Kyu Eun Lee Journal: Ann Surg Oncol Date: 2018-04-02 Impact factor: 5.344
Authors: Salvatore Piscuoglio; Charlotte Ky Ng; Melissa Murray; Kathleen A Burke; Marcia Edelweiss; Felipe C Geyer; Gabriel S Macedo; Akiko Inagaki; Anastasios D Papanastasiou; Luciano G Martelotto; Caterina Marchio; Raymond S Lim; Rafael A Ioris; Pooja K Nahar; Ino De Bruijn; Lillian Smyth; Muzaffar Akram; Dara Ross; John H Petrini; Larry Norton; David B Solit; Jose Baselga; Edi Brogi; Marc Ladanyi; Britta Weigelt; Jorge S Reis-Filho Journal: J Pathol Date: 2016-01-25 Impact factor: 7.996
Authors: Pedram Razavi; Matthew T Chang; Guotai Xu; Chaitanya Bandlamudi; Dara S Ross; Neil Vasan; Yanyan Cai; Craig M Bielski; Mark T A Donoghue; Philip Jonsson; Alexander Penson; Ronglai Shen; Fresia Pareja; Ritika Kundra; Sumit Middha; Michael L Cheng; Ahmet Zehir; Cyriac Kandoth; Ruchi Patel; Kety Huberman; Lillian M Smyth; Komal Jhaveri; Shanu Modi; Tiffany A Traina; Chau Dang; Wen Zhang; Britta Weigelt; Bob T Li; Marc Ladanyi; David M Hyman; Nikolaus Schultz; Mark E Robson; Clifford Hudis; Edi Brogi; Agnes Viale; Larry Norton; Maura N Dickler; Michael F Berger; Christine A Iacobuzio-Donahue; Sarat Chandarlapaty; Maurizio Scaltriti; Jorge S Reis-Filho; David B Solit; Barry S Taylor; José Baselga Journal: Cancer Cell Date: 2018-09-10 Impact factor: 31.743
Authors: Edaise M da Silva; Pier Selenica; Mahsa Vahdatinia; Fresia Pareja; Arnaud Da Cruz Paula; Lorenzo Ferrando; Andrea M Gazzo; Higinio Dopeso; Dara S Ross; Ariya Bakhteri; Nadeem Riaz; Sarat Chandarlapaty; Pedram Razavi; Larry Norton; Hannah Y Wen; Edi Brogi; Britta Weigelt; Hong Zhang; Jorge S Reis-Filho Journal: NPJ Breast Cancer Date: 2021-04-16